An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)

Saved in:
Bibliographic Details
Published in:Blood 2022-11, Vol.140 (Supplement 1), p.7476-7477
Main Authors: Stein, Anthony S., Bajel, Ashish, Fleming, Shaun, Jongen-Lavrencic, Mojca, Garciaz, Sylvain, Maiti, Abhishek, Boissel, Nicolas, De Botton, Stephane, Huls, Gerwin A., de Leeuw, David C., Avigan, David, Jensen, Kyle, Demers, Brigitte, Wagenaar, Timothy, Mi, Gu, Ziti-Ljajic, Samira, Draganov, Dobrin, Abbadessa, Giovanni, Wei, Andrew H
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c1850-a0d710b0bb17faebf18dffb166d5888fe41703f1e8eff719951287dfd1d2c8413
cites
container_end_page 7477
container_issue Supplement 1
container_start_page 7476
container_title Blood
container_volume 140
creator Stein, Anthony S.
Bajel, Ashish
Fleming, Shaun
Jongen-Lavrencic, Mojca
Garciaz, Sylvain
Maiti, Abhishek
Boissel, Nicolas
De Botton, Stephane
Huls, Gerwin A.
de Leeuw, David C.
Avigan, David
Jensen, Kyle
Demers, Brigitte
Wagenaar, Timothy
Mi, Gu
Ziti-Ljajic, Samira
Draganov, Dobrin
Abbadessa, Giovanni
Wei, Andrew H
description
doi_str_mv 10.1182/blood-2022-166000
format article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_166000</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497122048856</els_id><sourcerecordid>S0006497122048856</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1850-a0d710b0bb17faebf18dffb166d5888fe41703f1e8eff719951287dfd1d2c8413</originalsourceid><addsrcrecordid>eNp9kcFv0zAUhwMCiTI4cOT2jlSqmZ0mTSpOabfRSamGUjhHTvzcmqV2ZDub8t_j0B04cfKT9f0-Pb1fFH1m9CtjeXzddMYIEtM4Jmy1opS-jmYsjXNCaUzfRLPwsyLJOmPvovfO_aaUJcs4nb36VGh46FGTkjfYLeBOWeeJ0mQ3nLlewI1xSG5dyzvuldFw8IMYwUg4FFWSLNNsDYU4K62cR4sCCgcHpY8dQnFE7WEzwr32lj-hNoMLsxzc5FEafgRjQBw8K3-CCjveu2AwNszS8tYbO0LRDh5hP2JnlIASh0c8Kw5fqusKin05X8CGbLHrXsByPPcn03TcedX-g29IUZbzyb1TxxOplHu8SMXo-kBPzK4i-5vD_EP0VvLO4ceX9yr6dXf7c7sj5cP3-21RkpblKSWciozRhjYNyyTHRrJcSNmE44s0z3OJCcvoUjLMUcqMrdcpi_NMSMFE3OYJW15F7OJtrXHOoqx7q87cjjWj9dRp_bfTeuq0vnQaMt8uGQyLPSm0tWvDDVsUymLra2HUf9J_ALx_qY0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)</title><source>ScienceDirect Journals</source><creator>Stein, Anthony S. ; Bajel, Ashish ; Fleming, Shaun ; Jongen-Lavrencic, Mojca ; Garciaz, Sylvain ; Maiti, Abhishek ; Boissel, Nicolas ; De Botton, Stephane ; Huls, Gerwin A. ; de Leeuw, David C. ; Avigan, David ; Jensen, Kyle ; Demers, Brigitte ; Wagenaar, Timothy ; Mi, Gu ; Ziti-Ljajic, Samira ; Draganov, Dobrin ; Abbadessa, Giovanni ; Wei, Andrew H</creator><creatorcontrib>Stein, Anthony S. ; Bajel, Ashish ; Fleming, Shaun ; Jongen-Lavrencic, Mojca ; Garciaz, Sylvain ; Maiti, Abhishek ; Boissel, Nicolas ; De Botton, Stephane ; Huls, Gerwin A. ; de Leeuw, David C. ; Avigan, David ; Jensen, Kyle ; Demers, Brigitte ; Wagenaar, Timothy ; Mi, Gu ; Ziti-Ljajic, Samira ; Draganov, Dobrin ; Abbadessa, Giovanni ; Wei, Andrew H</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-166000</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.7476-7477</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1850-a0d710b0bb17faebf18dffb166d5888fe41703f1e8eff719951287dfd1d2c8413</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006497122048856$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3547,27923,27924,45779</link.rule.ids></links><search><creatorcontrib>Stein, Anthony S.</creatorcontrib><creatorcontrib>Bajel, Ashish</creatorcontrib><creatorcontrib>Fleming, Shaun</creatorcontrib><creatorcontrib>Jongen-Lavrencic, Mojca</creatorcontrib><creatorcontrib>Garciaz, Sylvain</creatorcontrib><creatorcontrib>Maiti, Abhishek</creatorcontrib><creatorcontrib>Boissel, Nicolas</creatorcontrib><creatorcontrib>De Botton, Stephane</creatorcontrib><creatorcontrib>Huls, Gerwin A.</creatorcontrib><creatorcontrib>de Leeuw, David C.</creatorcontrib><creatorcontrib>Avigan, David</creatorcontrib><creatorcontrib>Jensen, Kyle</creatorcontrib><creatorcontrib>Demers, Brigitte</creatorcontrib><creatorcontrib>Wagenaar, Timothy</creatorcontrib><creatorcontrib>Mi, Gu</creatorcontrib><creatorcontrib>Ziti-Ljajic, Samira</creatorcontrib><creatorcontrib>Draganov, Dobrin</creatorcontrib><creatorcontrib>Abbadessa, Giovanni</creatorcontrib><creatorcontrib>Wei, Andrew H</creatorcontrib><title>An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kcFv0zAUhwMCiTI4cOT2jlSqmZ0mTSpOabfRSamGUjhHTvzcmqV2ZDub8t_j0B04cfKT9f0-Pb1fFH1m9CtjeXzddMYIEtM4Jmy1opS-jmYsjXNCaUzfRLPwsyLJOmPvovfO_aaUJcs4nb36VGh46FGTkjfYLeBOWeeJ0mQ3nLlewI1xSG5dyzvuldFw8IMYwUg4FFWSLNNsDYU4K62cR4sCCgcHpY8dQnFE7WEzwr32lj-hNoMLsxzc5FEafgRjQBw8K3-CCjveu2AwNszS8tYbO0LRDh5hP2JnlIASh0c8Kw5fqusKin05X8CGbLHrXsByPPcn03TcedX-g29IUZbzyb1TxxOplHu8SMXo-kBPzK4i-5vD_EP0VvLO4ceX9yr6dXf7c7sj5cP3-21RkpblKSWciozRhjYNyyTHRrJcSNmE44s0z3OJCcvoUjLMUcqMrdcpi_NMSMFE3OYJW15F7OJtrXHOoqx7q87cjjWj9dRp_bfTeuq0vnQaMt8uGQyLPSm0tWvDDVsUymLra2HUf9J_ALx_qY0</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Stein, Anthony S.</creator><creator>Bajel, Ashish</creator><creator>Fleming, Shaun</creator><creator>Jongen-Lavrencic, Mojca</creator><creator>Garciaz, Sylvain</creator><creator>Maiti, Abhishek</creator><creator>Boissel, Nicolas</creator><creator>De Botton, Stephane</creator><creator>Huls, Gerwin A.</creator><creator>de Leeuw, David C.</creator><creator>Avigan, David</creator><creator>Jensen, Kyle</creator><creator>Demers, Brigitte</creator><creator>Wagenaar, Timothy</creator><creator>Mi, Gu</creator><creator>Ziti-Ljajic, Samira</creator><creator>Draganov, Dobrin</creator><creator>Abbadessa, Giovanni</creator><creator>Wei, Andrew H</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)</title><author>Stein, Anthony S. ; Bajel, Ashish ; Fleming, Shaun ; Jongen-Lavrencic, Mojca ; Garciaz, Sylvain ; Maiti, Abhishek ; Boissel, Nicolas ; De Botton, Stephane ; Huls, Gerwin A. ; de Leeuw, David C. ; Avigan, David ; Jensen, Kyle ; Demers, Brigitte ; Wagenaar, Timothy ; Mi, Gu ; Ziti-Ljajic, Samira ; Draganov, Dobrin ; Abbadessa, Giovanni ; Wei, Andrew H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1850-a0d710b0bb17faebf18dffb166d5888fe41703f1e8eff719951287dfd1d2c8413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stein, Anthony S.</creatorcontrib><creatorcontrib>Bajel, Ashish</creatorcontrib><creatorcontrib>Fleming, Shaun</creatorcontrib><creatorcontrib>Jongen-Lavrencic, Mojca</creatorcontrib><creatorcontrib>Garciaz, Sylvain</creatorcontrib><creatorcontrib>Maiti, Abhishek</creatorcontrib><creatorcontrib>Boissel, Nicolas</creatorcontrib><creatorcontrib>De Botton, Stephane</creatorcontrib><creatorcontrib>Huls, Gerwin A.</creatorcontrib><creatorcontrib>de Leeuw, David C.</creatorcontrib><creatorcontrib>Avigan, David</creatorcontrib><creatorcontrib>Jensen, Kyle</creatorcontrib><creatorcontrib>Demers, Brigitte</creatorcontrib><creatorcontrib>Wagenaar, Timothy</creatorcontrib><creatorcontrib>Mi, Gu</creatorcontrib><creatorcontrib>Ziti-Ljajic, Samira</creatorcontrib><creatorcontrib>Draganov, Dobrin</creatorcontrib><creatorcontrib>Abbadessa, Giovanni</creatorcontrib><creatorcontrib>Wei, Andrew H</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stein, Anthony S.</au><au>Bajel, Ashish</au><au>Fleming, Shaun</au><au>Jongen-Lavrencic, Mojca</au><au>Garciaz, Sylvain</au><au>Maiti, Abhishek</au><au>Boissel, Nicolas</au><au>De Botton, Stephane</au><au>Huls, Gerwin A.</au><au>de Leeuw, David C.</au><au>Avigan, David</au><au>Jensen, Kyle</au><au>Demers, Brigitte</au><au>Wagenaar, Timothy</au><au>Mi, Gu</au><au>Ziti-Ljajic, Samira</au><au>Draganov, Dobrin</au><au>Abbadessa, Giovanni</au><au>Wei, Andrew H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>7476</spage><epage>7477</epage><pages>7476-7477</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-166000</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2022-11, Vol.140 (Supplement 1), p.7476-7477
issn 0006-4971
1528-0020
language eng
recordid cdi_crossref_primary_10_1182_blood_2022_166000
source ScienceDirect Journals
title An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T11%3A03%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20Open-Label,%20First-in-Human,%20Dose-Escalation%20Study%20of%20SAR443579%20Administered%20As%20Single%20Agent%20By%20Intravenous%20Infusion%20in%20Patients%20with%20Relapsed%20or%20Refractory%20Acute%20Myeloid%20Leukemia%20(R/R%20AML),%20B-Cell%20Acute%20Lymphoblastic%20Leukemia%20(B-ALL)%20or%20High-Risk%20Myelodysplasia%20(HR-MDS)&rft.jtitle=Blood&rft.au=Stein,%20Anthony%20S.&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=7476&rft.epage=7477&rft.pages=7476-7477&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-166000&rft_dat=%3Celsevier_cross%3ES0006497122048856%3C/elsevier_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1850-a0d710b0bb17faebf18dffb166d5888fe41703f1e8eff719951287dfd1d2c8413%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true